Devita, Hellman, and Rosenberg's Cancer

LWBK1006-40 LWW-Govindan-Review December 12, 2011 20:33

512 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Question 40.14. All of the following risk factors are associated with shorter overall and

disease-free survival after neoadjuvant chemotherapy followed by resec-

tion for patients with colorectal liver metastases, EXCEPT:

A. Preoperative tumor size>10 cm

B. Preoperative CA 19-9>100 IU/L

C. Colon primary

D. More than three metastatic liver lesions at the time of operation

Question 40.15. The following statements are true of bisphosphonates use in metastatic

bone disease, EXCEPT:

A. Consensus recommendations indicate that all patients with myeloma

and radiologically confirmed bone metastasis from breast cancer

should receive bisphosphonates from the time of diagnosis and con-

tinue indefinitely.

B. Development of a skeletal-related event or progressive bone metasta-

sis while on pamidronate is an indication of ineffectiveness of bispho-

sphonates and benefit will not be obtained by switching to zoledronic

acid.

C. Bone resorption markers such as N-telopeptide of type I collagen

(NTx) may be useful to identify patients at high risk of skeletal com-

plications.

Question 40.16. All of the following statements regarding peritoneovenous shunt are true,

EXCEPT:

A. Has a unidirectional valve allowing flow from abdomen to chest and

preventing reflux.

B. Contraindicated with loculated effusions.

C. No increased risk of spreading malignant cells into the systemic cir-

culation.

D. Studies demonstrate control of ascites in 72% of patients with mean

shunt patency of 9.6 weeks.

E. No contraindications to shunt in cases of hemorrhagic ascites.